Government · Washington
White House drops FDA nominee Heidi Overton after bipartisan doubts in the Senate
The Trump administration withdrew the nomination of Heidi Overton, a White House health policy aide, a day before a Senate committee was due to vote on her. Republicans and Democrats had both questioned her views on vaccines and abortion.
AI text based on reports by ANSA.it, The Guardian, The New York Times and other publishers. Published . How it is made
For membersThe first 30 seconds for everyone. Synthetic voice (AI).
In brief
A senior administration official told Axios late on Tuesday, 17 November, that Heidi Overton lacked the Senate support needed for confirmation, one day before the 18 November committee vote.
Committee chairman Bill Cassidy called Overton's role in a summer executive order on childhood vaccine recommendations "almost disqualifying" and said he could not predict the outcome of the vote.
Overton's 2023 policy brief for the America First Policy Institute urged strict regulation of mifepristone, and Democrats were alarmed by her past statements on the drug.
Kyle Diamantas has been acting commissioner since Marty Makary resigned in May, and the administration must now find a new FDA candidate.
- September 2026Overton faces questions at her Senate confirmation hearing
- 17 NovWhite House withdraws her nomination on Tuesday night
- 18 NovSenate health committee vote had been scheduled for Wednesday morning
The withdrawal
The White House has withdrawn its nomination of Heidi Overton to lead the Food and Drug Administration. A senior administration official told Axios late on Tuesday, 17 November, that she lacked the support in the Senate needed to move forward with confirmation. The Senate Health, Education, Labor and Pensions Committee had been scheduled to vote on her nomination on Wednesday, 18 November, but it became clear on Tuesday night that she did not have enough votes. Overton, a physician and deputy director of the White House Domestic Policy Council, was nominated by Donald Trump in August. The agency is therefore still without a permanent commissioner, and the administration must now find a new candidate.
Doubts from both parties
The committee's chairman, Republican Senator Bill Cassidy of Louisiana, had voiced reservations about Overton from the start. He described her role in a summer executive order calling for fewer vaccines recommended for children as "almost disqualifying." On Sunday, Cassidy told CBS's Face the Nation that he could not predict the result of the vote.
“I cannot tell you the outcome of that vote right now.”
Democrats focused on abortion. Overton had called the abortion pill mifepristone dangerous to women, and in a 2023 policy brief for the America First Policy Institute she argued that Congress should strictly regulate it. At her hearing she said the drug was safe and effective as labeled under FDA regulations. Republicans on the panel were also uneasy that she gave only vague answers on how she would handle an ongoing safety review of mifepristone at the agency.
The September hearing
At her September confirmation hearing, Overton defended the measles, mumps and rubella vaccine, even though Trump has suggested the shot is deadly. She called the vaccine the best tool available for the measles outbreak.
“It is safe and effective and it is our best tool right now in the public health response to the measles outbreak.”
On other subjects she showed loyalty to the president, defending his decisions that career scientists usually make. She skirted questions about how she would keep her political independence at the agency and how she would regulate abortion pills if confirmed.
Kennedy's agenda and the FDA's leadership
A senior administration official said the agency needs a new direction and that the administration fully backs Health Secretary Robert F. Kennedy Jr.'s Make America Healthy Again agenda. Kyle Diamantas has served as acting commissioner since Marty Makary resigned in May. Makary's allies have described his exit as a matter of principle, saying he objected to allowing the sale of fruit-flavored vapes. Overton's August nomination had been read as an effort to install a steadier Trump loyalist after a turbulent year at the agency.
Reactions and what comes next
Reproductive Freedom for All, formerly Naral Pro-Choice America, welcomed the decision. Its president and CEO, Mini Timmaraju, said:
“Heidi Overton posed a serious threat to the future of medication abortion access.”
The Washington Post reported that the administration is unlikely to see an FDA chief confirmed anytime soon. Democrats won sweeping victories in the midterm elections and will control Congress next year.
This article is part of a thread
The 2026 US midterm elections
What changed since this entry:
- 18/11White House withdrew Heidi Overton's FDA nomination a day before a Senate committee vote
Ask about this text
Sources and context
- ANSA.itTrump withdraws controversial nomination to lead the Food and Drug AdministrationTrump ritira la controversa nomina per la guida della Food and Drug Administration - Ultima ora · original in Italian
- The GuardianWhite House withdraws nomination of Heidi Overton to lead FDA
- The New York TimesWhite House Withdraws Nomination of Heidi Overton to Be F.D.A. Commissioner
- Washington PostWhite House pulls FDA nominee amid bipartisan pushback
- Heidi Overton
- Physician and deputy director of the White House Domestic Policy Council whose FDA nomination was withdrawn
- Bill Cassidy
- Republican senator from Louisiana who chairs the Senate Health, Education, Labor and Pensions Committee
- Donald Trump
- President who nominated Overton in August
- Robert F. Kennedy Jr.
- Health and Human Services Secretary whose Make America Healthy Again agenda shaped the nomination debate
- Marty Makary
- Former FDA commissioner who resigned in May
- Kyle Diamantas
- Acting FDA commissioner since Makary's resignation
- Mini Timmaraju
- President and CEO of Reproductive Freedom for All
- Places
- Washington, United States, Washington, D.C., Louisiana
Pollar is free and carries no ads in the text. Its members keep it going.
Support Pollar